| Literature DB >> 28322696 |
Duck Woong Park, Sun-Hee Kim, Jung Wook Park, Min-Ji Kim, Sun Ju Cho, Hye Jung Park, So Hyang Jung, Mi Hee Seo, Yong Seok Lee, Byung Hee Kim, Hyeran Min, Su Ya Lee, Dong Ryong Ha, Eun Sun Kim, Yeongjin Hong, Jae Keun Chung.
Abstract
The incidence rate for scarlet fever in South Korea is rising. During 2008-2015, we collected group A Streptococcus isolates and performed emm and exotoxin genotyping and disk-diffusion antimicrobial tests. Scarlet fever in South Korea was most closely associated with emm types emm4, emm28, emm1, and emm3. In 2015, tetracycline resistance started increasing.Entities:
Keywords: South Korea; Streptococcus pyogenes; antimicrobial resistance; bacteria; disk diffusion antimicrobial tests; emm; exotoxin; group A strep; scarlet fever; streptococci; virulence factors
Mesh:
Substances:
Year: 2017 PMID: 28322696 PMCID: PMC5367408 DOI: 10.3201/eid2304.160773
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Incidence of scarlet fever in Gwangju, South Korea, 2008–2015. A) The number of cases per 100,000 persons in Gwangju and South Korea. B) Distribution of cases by month of each year.
Figure 2emm type characterization of group A Streptococcus isolates from patients with scarlet fever, Gwangju, South Korea, 2008–2015. A) Annual fluctuations of emm types. Number of isolates by year: 7 in 2008, 11 in 2009, 9 in 2010, 66 in 2011, 74 in 2012, 147 in 2013, 107 in 2014, and 284 in 2015. B) Total number of isolates by emm type. Others refers to rarely found emm types (emm11, emm13, emm17, emm23, emm26, emm30, emm31, emm43, emm49, emm59, emm81, emm82, emm87, emm101, emm107, emm131, emm135, emm161, emm163, emm174, emm183, emm196, emm203, emm204, emm227, emm236, and emm241).
Characterization of antimicrobial drug resistance according to emm types in Gwangju, South Korea, 2008–2015*
| Year, antimicrobial drug | ||||||
|---|---|---|---|---|---|---|
| Others | Total | |||||
| 2008 | ||||||
| Tetracycline | – | 1† | – | – | – | 1† |
| 2009 | ||||||
| Erythromycin | – | – | – | 2 | – | 2 |
| Clindamycin | – | – | – | 2 | – | 2 |
| Tetracycline | – | – | – | 1 | – | 1 |
| 2010 | ||||||
| Erythromycin | – | – | – | 1 | – | 1 |
| Clindamycin | – | – | – | 1 | – | 1 |
| 2011 | ||||||
| Erythromycin | – | 1 | – | 1 | 1† | 1/3† |
| Clindamycin | – | 1 | – | 1 | – | 2 |
| Tetracycline | – | – | – | 1 | – | 1 |
| 2012 | ||||||
| Erythromycin | – | – | – | 1 | – | 1 |
| Clindamycin | – | 1 | – | 1 | – | 2 |
| Tetracycline | – | 1 | – | – | – | 1 |
| 2013 | ||||||
| Chloramphenicol | 1 | – | – | – | – | 1 |
| Erythromycin | 1 | – | – | 2 | 1† | 1/4† |
| Clindamycin | – | 1 | – | 2 | – | 3 |
| Tetracycline | – | 1 | – | 1 | – | 2 |
| 2014 | ||||||
| Chloramphenicol | – | – | 1† | – | – | 1† |
| Erythromycin | – | – | – | 4 | – | 4 |
| Clindamycin | – | – | – | 4 | – | 4 |
| Tetracycline | – | 1† | – | 4 | – | 1/5† |
| 2015 | ||||||
| Erythromycin | – | – | 1 | 5 | – | 6 |
| Clindamycin | – | – | 1 | 5 | – | 6 |
| Tetracycline | 22/23† | – | 1 | 2/7† | 5/7† | 29/38† |
| Isolates, % (no./total) | 24.5% (25/102) | 3.2% (8/251) | 10.8% (4/37) | 17.3% (18/104)‡ | 4.3% (9/211) | 9.1% (64/705) |
| p value | <0.01 | <0.01 | <0.01 | |||
*Dashes indicate no isolates were drug resistant. †Intermediate resistance. With fractions, the numerator indicates the number of isolates with intermediate resistance, and the denominator indicates the total number of resistant isolates. ‡Numbers in column do not add up to 18 (the number of isolates) because of multidrug resistance.